IngentaConnect Histological effects of esomeprazole therapy on the squamous epit...

Authors: VIETH, M.¹; KULIG, M.²; LEODOLTER, A.³; NAUCLÉR, E.⁴; JASPERSEN, D.⁵; LABENZ, J.⁶; MEYER-SABELLEK, W.⁷; LIND, T.⁴; WILLICH, S.²; MALFERTHEINER, P.³; STOLTE, M.¹

Source: Alimentary Pharmacology & Therapeutics, Volume 23, Number 2, January 2006 , pp. 313-319(7)

Publisher: Blackwell Publishing

Abstract:

Summary Background

Proton pump inhibitor therapy has been reported to reduce proliferative changes of the oesophagus significantly in gastro-oesophageal reflux disease (GERD). <link rid="q2"> Aim

To assess the histological effects of esomeprazole treatment on the oesophagus. Methods

Data were derived from a subgroup of patients participating in the proGERD study, who had either erosive reflux disease (n = 720) or non-erosive reflux disease (n = 35) and who had biopsy data from two sites [(i) 2 cm above the z-line and (ii) at the z-line], obtained at baseline and following treatment with esomeprazole. Proliferative changes of the squamous epithelium were assessed histologically by measuring thickness of the basal cell layer and elongation of the papillae as a percentage of the whole epithelial thickness. Results

In erosive reflux disease patients, the thickness of the basal cell layer and length of the papillae pretreatment were associated with the severity of oesophagitis (P < 0.05), at both biopsy sites. After esomeprazole treatment, baseline thickness and length of papillae were significantly reduced (P < 0.05) at both biopsy sites in non-erosive reflux disease and erosive reflux disease patients (particularly those with Los Angeles grades C and D). Conclusion

This demonstrates a strong correlation between severity of GERD and histological parameters. Esomeprazole therapy resulted in clear reversal of proliferative changes observed prior to treatment in the squamous epithelium at both biopsy locations.

Document Type: Research article

DOI: 10.1111/j.1365-2036.2006.02752.x

Affiliations: 1: Institute of Pathology, Klinikum Bayreuth, Bayreuth, Germany 2: University Hospital, Charité, Berlin, Germany 3: Department of Gastroenterology and Hepatology, Otto-von-Guericke University, Magdeburg, Germany 4: AstraZeneca R&D Mölndal, Sweden 5: Department of Medicine II, Klinikum Fulda, Fulda, Germany 6: Ev.-Jung-Stilling Krankenhaus, Siegen, Germany 7: AstraZeneca GmbH, Wedel, Germany

You have access to the full text article on a website external to Ingentaconnect.

Please click here to view this article on Synergy.

You may be required to register and activate access on Synergy before you can obtain the full text. If you have any queries please contact onlinehelp@oxon.blackwellpublishing.com

Histological effects of esomeprazole therapy on the squamous epithelium of the distal oesophagus